6125-33-3

Basic information

• Product Name: 2-CHLORO-N-[4-(3-NITRO-PHENYL)-THIAZOL-2-YL]-ACETAMIDE
• Synonyms: Thiazole,2-(2-chloroacetamido)-4-(m-nitrophenyl)- (7CI,8CI)
• CAS NO: 6125-33-3
• Molecular Formula: C₁₁H₈ClN₃O₃S
• Molecular Weight: 297.72
• Mol File: 6125-33-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 216 °C(Solv: ethanol (64-17-5))
• Appearance: /
• Density: 1.536g/cm³
• Refractive Index: 1.677
• PKA: 7.01±0.50(Predicted)
• CAS DataBase Reference: 2-CHLORO-N-[4-(3-NITRO-PHENYL)-THIAZOL-2-YL]-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-[4-(3-NITRO-PHENYL)-THIAZOL-2-YL]-ACETAMIDE(6125-33-3)
• EPA Substance Registry System: 2-CHLORO-N-[4-(3-NITRO-PHENYL)-THIAZOL-2-YL]-ACETAMIDE(6125-33-3)

Safety Data

• Hazardous Substances Data: 6125-33-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H8ClN3O3S/c12-5-10(16)14-11-13-9(6-19-11)7-2-1-3-8(4-7)15(17)18/h1-4,6H,5H2,(H,13,14,16)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 2227-64-7 3'-nitro-2-bromoacetophenone 
• 121-89-1 3-Nitroacetophenone 
• 57493-24-0 4-(3-nitrophenyl)thiazol-2-ylamine 

Downstream Products

• 91402-09-4 2-Isopropylamino-N-[4-(3-nitro-phenyl)-thiazol-2-yl]-acetamide 
• 91402-12-9 2-tert-Butylamino-N-[4-(3-nitro-phenyl)-thiazol-2-yl]-acetamide 
• 91402-08-3 2-Ethylamino-N-[4-(3-nitro-phenyl)-thiazol-2-yl]-acetamide 
• 91402-10-7 2-Isobutylamino-N-[4-(3-nitro-phenyl)-thiazol-2-yl]-acetamide 
• 91402-11-8 2-(N-sec-butylaminoacetamido)-4-m-nitrophenylthiazole 

Relevant articles and documents

Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition

A series of novel hybrid compounds of hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine with aminothiazole scaffolds were synthesized. The synthesized compounds were evaluated for their cytotoxic activity against the NCI-60 human tumor cell line panel. Compounds 7c, 7d and 7e exhibited significant antiproliferative activities at 10?5 M dose. Compound 7c exhibited excellent cytotoxic activity against CNS cancer cell lines including SNB-75 and SF-295 as well as renal cancer cell line CAKI-1 when compared with sorafenib as standard anticancer drug. In addition, compound 7d showed almost comparable anticancer activity to sorafenib against SNB-75 cell line and displayed moderate activity against SF-295 and CAKI-1 cell lines in comparison to sorafenib. Compound 7c inhibited the vascular endothelial growth factor receptor 2 (VEGFR-2) with IC50 of 62.48 ± 3.7 nM and decreased both total VEGFR-2 and phosphorylated VEGFR-2 in treated SNB-75 cells suggesting its ability to down regulate cell proliferation, growth, and survival. The flow cytometric analysis showed that 7c displayed its cytotoxic activity through the reduction of the cellular proliferation and induction of cell cycle arrest at the G2/M phase. Compound 7c clearly boosted the level of the apoptotic caspase-3. All the synthesized compounds were also screened for their antibacterial and antifungal activity against four pathogenic strains of both Gram-positive and Gram-negative as well as Candida albicans. Only compound 7d exhibited antifungal activity against Candida albicans compared to nystatin as the standard antifungal compound.

Β - secretase enzyme has the function of inhibiting compound, the preparation of the compounds and use thereof

The invention discloses a compound capable of inhibiting beta-secretase, and a preparation method and application thereof. The structure of the compound is shown in a formula I, formula II or formula III as described in the specification. In the formula I, X is S or NH; R1 is selected from hydrogen and nitro group; R2 and R4 are same or different and independently selected from the group consisting of hydrogen, halogen, nitro group and substituted aryl group; R3 is selected from the group consisting of hydrogen, nitro group, straight-chain and branched-chain alkyl and substituted alkyl groups with a carbon number of 1 to 4, alkylamino or alkyloxy group with a carbon number of 1 to 4 and alkylamido group with a carbon number of 1 to 4; R is located at position 2, 3 or 4 of a benzene ring and selected from the group consisting of hydrogen, straight-chain and branched-chain alkyl and substituted alkyl groups with a carbon number of 1 to 4, alkylamino or alkyloxy group with a carbon number of 1 to 4 and alkylamido group with a carbon number of 1 to 4. In the formula II, R is selected from different substituted aryl groups. In the formula III, R is selected from hydrogen or cyano group. Experiments prove that the compound provided by the invention has good beta-secretase inhibitory activity and has wide application values as a beta-secretase inhibitor.

2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and?docking studies

In this work, a series of 2-substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamide derivatives were developed as β-secretase (BACE-1) inhibitors. Supported by docking study, a small library of derivatives were designed, synthesized and biologically evaluated in vitro. In addition, the selected compounds were tested with affinity (KD) towards BACE-1, blood brain barrier (BBB) permeability and cytotoxicity. The studies revealed that the most potent analog 41 (IC50 = 4.6 μM) with high predicted BBB permeability and low cellular cytotoxicity, could serve as a good lead structure for further optimization.